The pathways related to glutamine metabolism, glutamine inhibitors and their implication for improving the efficiency of chemotherapy in triple-negative breast cancer
Mutation Research/Reviews in Mutation Research · 2021-01 · 787 · 108366
DOI: 10.1016/j.mrrev.2021.108366 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Mutation Research/Reviews in Mutation Research, 2021-01. Verfasst von Soheila Delgir und 5 weiteren Autor:innen. Beteiligte Einrichtung: Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 103 Literaturangaben. Gefördert von: Tabriz University of Medical Sciences.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Breast cancer (BC) is a heterogeneous cancer with multiple subtypes affecting women worldwide. Triple-negative breast cancer (TNBC) is a prominent subtype of BC with poor prognosis and an aggressive phenotype. Recent understanding of metabolic reprogramming supports its role in the growth of cancer cells and their adaptation to their microenvironment. The Warburg effect is characterized by the shift from oxidative to reductive metabolism and external secretion of lactate. The Warburg effect prevents the use of the required pyruvate in the tricarboxylic acid (TCA) cycle progressing through pyruvate dehydrogenase inactivation. Therefore, it is a major regulatory mechanism to promote glycolysis and disrupt the TCA cycle. Glutamine (Gln) can supply the complementary energy for cancer cells. Additionally, it is the main substrate to support bioenergetics and biosynthetic activities in cancer cells and plays a vital role in a wide array of other processes such as ferroptosis. Thus, the switching of glucose to Gln in the TCA cycle toward reductive Gln metabolism is carried out by hypoxia-inducible factors (HIFs) conducted through the Warburg effect. The literature suggests that the addiction of TNBC to Gln could facilitate the proliferation and invasiveness of these cancers. Thus, Gln metabolism inhibitors, such as CB-839, could be applied to manage the carcinogenic properties of TNBC. Such inhibitors, along with conventional chemotherapy agents, can potentially improve the efficiency and efficacy of TNBC treatment. In this review, we discuss the associations between glucose and Gln metabolism and control of cancer cell growth from the perspective that Gln metabolism inhibitors could improve the current chemotherapy drug effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
- Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
- Department of Immunology and Allergy, Academic Center for Education, Culture, and Research (ACECR), Tehran, Iran.
- Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: alivandm@tbzmed.ac.ir.
Förderung
- Tabriz University of Medical Sciences
Zitieren
APA
Delgir, S., Bastami, M., Ilkhani, K., Safi, A., Seif, F., & Alivand, M. R. (2021). The pathways related to glutamine metabolism, glutamine inhibitors and their implication for improving the efficiency of chemotherapy in triple-negative breast cancer. Mutation Research/Reviews in Mutation Research, 787, 108366. https://doi.org/10.1016/j.mrrev.2021.108366
Vancouver
Delgir S, Bastami M, Ilkhani K, Safi A, Seif F, Alivand MR. The pathways related to glutamine metabolism, glutamine inhibitors and their implication for improving the efficiency of chemotherapy in triple-negative breast cancer. Mutation Research/Reviews in Mutation Research. 2021;787:108366. doi:10.1016/j.mrrev.2021.108366
BibTeX
@article{Delgir2021,
author = {Delgir, Soheila and Bastami, Milad and Ilkhani, Khandan and Safi, Asma and Seif, Farhad and Alivand, Mohammad Reza},
title = {The pathways related to glutamine metabolism, glutamine inhibitors and their implication for improving the efficiency of chemotherapy in triple-negative breast cancer},
journal = {Mutation Research/Reviews in Mutation Research},
year = {2021},
volume = {787},
pages = {108366},
doi = {10.1016/j.mrrev.2021.108366}
}
EUVIMED